EUVIMEDEUVIMED entdecken
Systematische Übersicht

Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety

Aditi Chokshi iD, Jennifer Keelin, Valerie Foy, Sourab Choudhury, Daniel Fischer

Pediatric Dermatology · 2026

DOI: 10.1111/pde.70298 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Aditi Chokshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Pyrazoles. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a common inflammatory skin disease affecting up to 20% of children. Long‐term topical management is often limited by safety concerns, tolerability issues, and caregiver hesitancy. Topical janus kinase (JAK) inhibitors have emerged as targeted nonsteroidal therapies, with recent pediatric approval of ruxolitinib expanding treatment options. This systematic review synthesizes pediatric‐only evidence on topical JAK inhibitors for AD, focusing on efficacy, safety, and treatment strategies for clinical practice.

Methods

A PRISMA‐guided systematic review of PubMed, Embase, Web of Science, and ClinicalTrials.gov was conducted through November 2025. Eight studies met inclusion criteria, encompassing 541 pediatric patients treated with ruxolitinib or delgocitinib.

Results

Across randomized and extension studies, both agents produced rapid, clinically meaningful improvements in both disease severity and pruritus, with benefits observed within the first several weeks of treatment. Ruxolitinib showed consistent efficacy in patients with both limited and extensive disease involvement, while delgocitinib showed sustained disease control with continuous use, including in younger children and infants. Topical JAK inhibitors were generally well tolerated, with adverse event rates comparable to vehicle and few discontinuations. Application‐site reactions were uncommon, and no treatment‐related serious AEs were reported.

Conclusions

Overall, available pediatric data supports topical JAK inhibitors as effective and well‐tolerated nonsteroidal options for AD, providing rapid symptom relief and disease control that may help expand steroid‐sparing treatment options for children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsPyrazolesHumansChildNitrilesPyrimidinesTreatment OutcomeAdministration, TopicalPyrrolesAdministration, CutaneousChild, Preschool

Stichwörter der Autor:innen

atopic dermatitisdelgocitinibjanus kinase inhibitorpediatricruxolitinib

Substanzen

Janus Kinase InhibitorsNitrilesruxolitinibPyrazolesPyrimidinesdelgocitinibPyrroles

Autor:innen und Institutionen

  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
  • Department of Dermatology, St. John's Episcopal Hospital, Far Rockaway, New York, USA.
  • The Dermatology Specialists, New York, New York, USA.
  • SINY Dermatology, Brooklyn, New York, USA.
  • The Ronald O. Perelman Department of Dermatology, NYU Langone Health Hospital, Brooklyn, New York, USA.

ORCID-Profile: Aditi Chokshi

Zitieren

APA

Chokshi, A., Keelin, J., Foy, V., Choudhury, S., & Fischer, D. (2026). Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology. https://doi.org/10.1111/pde.70298

Vancouver

Chokshi A, Keelin J, Foy V, Choudhury S, Fischer D. Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology. 2026. doi:10.1111/pde.70298

BibTeX
@article{Chokshi2026,
  author = {Chokshi, Aditi and Keelin, Jennifer and Foy, Valerie and Choudhury, Sourab and Fischer, Daniel},
  title = {Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety},
  journal = {Pediatric Dermatology},
  year = {2026},
  doi = {10.1111/pde.70298}
}
Kostenlos starten →